Prominent publications by Paul Haluska

KOL Index score: 42 . I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal antibody designed to bind and inhibit function of the type I insulin-like growth factor receptor (IGF-1R). Ganitumab was tested in combination with metformin and paclitaxel (PGM) followed by AC compared to standard-of-care alone. While ...

Key People For Purkinje Cell

Top KOLs in the world
Constantino Sotelo
purkinje cells mutant mice cerebellar cortex
Rodolfo R Llinás
purkinje cells squid giant synapse transmitter release
Joseph Altman
cerebellar cortex purkinje cells molecular layer
Francis Crépel
purkinje cells climbing fibres multiple innervation
Masanobu Masanobu
purkinje cells synapse elimination synaptic transmission
Chris Innocentius De Zeeuw
purkinje cells cerebellar nuclei inferior olive

Paul Haluska:Expert Impact

Concepts for whichPaul Haluskahas direct influence:Purkinje cell,  Presenting symptom,  Standard neoadjuvant therapy,  Combination metformin,  Pca1igg autoantibodies,  Ganitumab ganitumab response,  Patient pain.

Paul Haluska:KOL impact

Concepts related to the work of other authors for whichfor which Paul Haluska has influence:Autoimmune pain,  Rad51 gene expression,  Peripheral neuropathies,  Aggressive biology,  Cancer drug resistance,  Rppa proteomic analysis,  Protein array.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Mayo Clinic Rochester c/o Merck Corporation, 126 E. Lincoln Ave Rahway, New Jersey, 07065 USA | Mayo Clinic Department of Medical Oncology Rochester Minnesota USA

FREE Custom List